论文部分内容阅读
目的:探讨中药喜丹汤联合化疗治疗广泛期小细胞肺癌能否提高疗效。方法:经病理明确诊断的未经手术治疗的120例广泛期小细胞肺癌患者,随机分为对照组与研究组各60例,对照组采用EP方案化疗治疗,研究组采用中药喜丹汤联合EP方案治疗。结果:研究组与对照组总有效率(CR+PR)分别为75.0%(45/60)、56.7%(33/60),两组比较有统计学差异(P<0.05),中位生存时间及生存时间曲线:研究组10.9个月(10.5~11.2);对照组8.1个月(7.4~8.8),两组比较有显著的统计学意义(P<0.001);1年生存率研究组为53.3%(32/60),对照组为31.7%(19/60),两组比较差异有统计学意义(P<0.05);常见的毒副反应主要表现为血液学毒性及胃肠道反应,患者均可耐受。结论:中药联合化疗能提高广泛期小细胞肺癌的疗效,延长其生存期。
Objective: To investigate whether traditional Chinese medicine xidan decoction combined with chemotherapy can improve the curative effect of extensive stage small cell lung cancer. Methods: A total of 120 patients with extensive-stage small-cell lung cancer who were diagnosed by pathology without surgery were randomly divided into control group and study group with 60 cases each. The control group was treated with EP regimen. The study group was treated with traditional Chinese medicine Xidan Decoction combined with EP Program treatment. Results: The total effective rate (CR + PR) in study group and control group were 75.0% (45/60) and 56.7% (33/60), respectively. There was significant difference between the two groups (P <0.05) (P <0.001). The 1-year survival rate was 53.3 in the study group (10.5 to 11.2) and 8.1 months (7.4 to 8.8) in the control group % (32/60) in the control group and 31.7% (19/60) in the control group, with significant difference between the two groups (P <0.05). Common toxicities were mainly hematological toxicity and gastrointestinal reactions. Can be tolerated. Conclusion: The combination of traditional Chinese medicine and chemotherapy can enhance the efficacy of extended-stage small cell lung cancer and prolong its survival.